960404-48-2
960404-48-2
Chemical Structure
Dapagliflozin ((2S)-1,2-propanediol, hydrate)
Synonym(s): BMS-512148 (2S)-1,2-propanediol, hydrate
- CAS No.: 960404-48-2
- Formula:C24H35ClO9
- Molecular Weight:502.98
IUPAC Name: (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol compound with (S)-propane-1,2-diol (1:1) hydrate
InChIKey: GOADIQFWSVMMRJ-UPGAGZFNSA-N
SMILES: O[C@H]1[C@H](C2=CC(CC3=CC=C(OCC)C=C3)=C(Cl)C=C2)O[C@H](CO)[C@@H](O)[C@@H]1O.C[C@H](O)CO.O
Biological Activity: Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine[1]. Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dapagliflozin ((2S)-1,2-propanediol, hydrate) | 99.97% | Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) | ≥98% | Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) is the analytical standard of Dapagliflozin ((2S)-1,2-propanediol, hydrate). This product is intended for research and analytical applications. Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dapagliflozin | 99.95% | Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tianagliflozin | 99.96% | Tianagliflozin is a sodium/glucose cotransporter 2 (SGLT-2) inhibitor with potential for investigation in type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
fluoro-Dapagliflozin | fluoro-Dapagliflozin, a structural analog of Dapagliflozin, is a selective SGLT2 inhibitor with Ki values of 5.3 nM and 330 nM for SGLT2 and SGLT1, respectively. fluoro-Dapagliflozin blocks glucose transport and glucose-coupled currents. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
galacto-Dapagliflozin | Galacto-dapagliflozin is a selective inhibitor for hSGLT2 with Ki of 25 nM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Empagliflozin (Standard) | 99.94% | Empagliflozin (Standard) is the analytical standard of Empagliflozin. This product is intended for research and analytical applications. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bexagliflozin | 98.81% | Bexagliflozin (EGT1442; EGT0001442; THR-1442) is an orally active and selective SGLT2 inhibitor with IC50 values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin selectively inhibits SGLT2-mediated sodium-dependent glucose uptake. Bexagliflozin induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin reduces blood glucose and HbA1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin can be used for the research of type 2 diabetes mellitus, hypertensive stroke. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dapagliflozin impurity 111 (Standard) | ≥98% | (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-methoxyphenyl)methyl]phenyl]-D-glucitol (Standard) is the analytical standard of (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-methoxyphenyl)methyl]phenyl]-D-glucitol. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SGLT2-IN-1 (Standard) | ≥98% | SGLT2-IN-1 (standard) is the analytical standard for SGLT2-IN-1. This product is used for research and analytical applications. SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC50 of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (Standard) | ≥98% | (2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (Standard) is the analytical standard of (2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (HY-I1122). This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dapagliflozin methyl acetate | Dapagliflozin methyl acetate is an orally active SGLT2 inhibitor. Dapagliflozin methyl acetate may be used in type 2 diabetes research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pedersen MG, et al. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci Rep. 2016 Aug 18;6:31214. [Content Brief]
- [2]. Chang YK, et al. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury. PLoS One. 2016 Jul 8;11(7):e0158810. [Content Brief]
